Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in inactive thyroid eye disease
NCT07113262Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sycume in thyroid eye disease (TED), sponsored by Innovent Biologics. Started Sep 2025; status: recruiting.
02
Drugs
sycume
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07113262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113262.